BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Science. Official publication website can be found on muni.cz.
Authors

PACULOVÁ Hana KRAMARA Juraj ŠIMEČKOVÁ Šárka FEDR Radek SOUČEK Karel HYLSE Ondřej PARUCH Kamil SVOBODA Marek MISTRÍK Martin KOHOUTEK Jiří

Year of publication 2017
Type Article in Periodical
Magazine / Source Tumor Biology
MU Faculty or unit

Faculty of Science

Citation
Web https://doi.org/10.1177/1010428317727479
Doi http://dx.doi.org/10.1177/1010428317727479
Field Organic chemistry
Keywords DNA damage response; BRCA1; CDK12; CHK1 inhibitor; transcription
Description A broad spectrum of tumors develop resistance to classic chemotherapy, necessitating the discovery of new therapies. One successful strategy exploits the synthetic lethality between poly(ADP-ribose) polymerase 1/2 proteins and DNA damage response genes, including BRCA1, a factor involved in homologous recombination–mediated DNA repair, and CDK12, a transcriptional kinase known to regulate the expression of DDR genes. CHK1 inhibitors have been shown to enhance the anti-cancer effect of DNA-damaging compounds. Since loss of BRCA1 increases replication stress and leads to DNA damage, we tested a hypothesis that CDK12- or BRCA1-depleted cells rely extensively on S-phase-related CHK1 functions for survival. The silencing of BRCA1 or CDK12 sensitized tumor cells to CHK1 inhibitors in vitro and in vivo. BRCA1 downregulation combined with CHK1 inhibition induced excessive amounts of DNA damage, resulting in an inability to complete the S-phase. Therefore, we suggest CHK1 inhibition as a strategy for targeting BRCA1- or CDK12-deficient tumors.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.